These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28554411)

  • 41. A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies.
    Bellomo G; Paolini Paoletti F; Chipi E; Petricciuolo M; Simoni S; Tambasco N; Parnetti L
    Diagnostics (Basel); 2020 Nov; 10(12):. PubMed ID: 33256252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.
    Compta Y; Ibarretxe-Bilbao N; Pereira JB; Junqué C; Bargalló N; Tolosa E; Valldeoriola F; Muñoz E; Camara A; Buongiorno M; Martí MJ
    Parkinsonism Relat Disord; 2012 Sep; 18(8):941-7. PubMed ID: 22595621
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.
    Compta Y; Martí MJ; Ibarretxe-Bilbao N; Junqué C; Valldeoriola F; Muñoz E; Ezquerra M; Ríos J; Tolosa E
    Mov Disord; 2009 Nov; 24(15):2203-10. PubMed ID: 19795497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease.
    Kang JH
    J Mov Disord; 2016 May; 9(2):89-96. PubMed ID: 27240810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies.
    Tang W; Huang Q; Wang Y; Wang ZY; Yao YY
    J Neurol Sci; 2014 Oct; 345(1-2):26-36. PubMed ID: 25086857
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CSF biomarkers and clinical progression of Parkinson disease.
    Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
    Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review.
    Andersen AD; Binzer M; Stenager E; Gramsbergen JB
    Acta Neurol Scand; 2017 Jan; 135(1):34-56. PubMed ID: 26991855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study.
    Yu SY; Zuo LJ; Wang F; Chen ZJ; Hu Y; Wang YJ; Wang XM; Zhang W
    BMC Neurol; 2014 May; 14():113. PubMed ID: 24884485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis.
    Parnetti L; Cicognola C; Eusebi P; Chiasserini D
    Biomark Med; 2016; 10(1):35-49. PubMed ID: 26643452
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
    Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
    Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.
    Mollenhauer B; Trenkwalder C; von Ahsen N; Bibl M; Steinacker P; Brechlin P; Schindehuette J; Poser S; Wiltfang J; Otto M
    Dement Geriatr Cogn Disord; 2006; 22(3):200-8. PubMed ID: 16899997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
    PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment.
    Mattsson N; Portelius E; Rolstad S; Gustavsson M; Andreasson U; Stridsberg M; Wallin A; Blennow K; Zetterberg H
    J Alzheimers Dis; 2012; 30(4):767-78. PubMed ID: 22475796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Sierra-Rio A; Balasa M; Olives J; Antonell A; Iranzo A; Castellví M; Bosch B; Grau-Rivera O; Fernandez-Villullas G; Rami L; Lladó A; Sánchez-Valle R; Molinuevo JL
    Neurodegener Dis; 2016; 16(1-2):69-76. PubMed ID: 26560503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.